Thrombotargets and Instituto Biomar Sign Drug Discovery Collaboration
News May 09, 2007
Under the terms of this agreement, Instituto Biomar will provide Thrombotargets Corp with its libraries of purified natural products and extracts collection for its High Throughput Screening of Pathway Activity (HTS-PA) in Thrombotargets’ technology.
Thrombotargets will seek to identify and optimize drug candidates for multiple targets that will be jointly developed by both companies.
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE